Incretin-based therapies and cardiovascular risk

References

• Ahrén B. The future of incretin-based therapy: novel avenues–novel targets. Diabetes Obes Metab 2011;13(Suppl 1):158-66. doi: 10.1111/j.1463-1326.2011.01457.x
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Bailey CJ, Del Prato S, . Management of type 2 diabetes: new and future developments in treatment. Lancet 2011;378:182-9
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• FDA Endocrinological and Metabolic Drugs Advisory Committee. FDA guideline for endocrinologic and metabolic drugs. Available: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabol icDrugsAdvisoryCommittee/UCM148659.pdf. [Accessed December 27, 2011]
   Google Scholar
• LEADER (Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results—a long-term evaluation). Identifier NCT01179048. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01179048?term=nct01179048&rank=1. [Accessed December 27, 2011]
   Google Scholar
• EXSCEL (Exenatide study of cardiovascular event lowering trial: a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus). Identifier: NCT01144338. Available at: http://clinicaltrials.gov/ct2/show/NCT01144338. [Accessed December 27, 2011]
   Google Scholar
• SAVOR-TIMI 53 (Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications). Identifier: NCT01107886. Available at: http://clinicaltrials.gov/ct2/show/NCT01107886?term=type+2+diabetes+mellitus+and+cardiovascular+disease&rank=37. [Accessed December 27, 2011]
   Google Scholar
• TECOS (Sitagliptin cardiovascular outcome study). Identifier: NCT 00790205. Available at: http://clinicaltrials.gov/ct2/show/NCT00790205. [Accessed December 27, 2011]
   Google Scholar
• Cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE). Identifier: NCT00968708. Available at: http://clinicaltrials.gov/ct2/show/NCT00968708. [Accessed December 27, 2011]
   Google Scholar
• CAROLINA: Cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. Identifier: NCT01243424. Available at: http://clinicaltrials.gov/ct2/show/NCT01243424. [Accessed December 27, 2011]
   Google Scholar
• Researching cardiovascular events with a weekly incretin (dulaglutide) in diabetes (REWIND). Identifier: NCT01394952. Available at: http://clinicaltrials.gov/ct2/show/NCT01394952?term=incretin+and+cardiovascular&rank=1. [Accessed December 27, 2011]
   Google Scholar
• Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764
   PubMedGoogle Scholar
• Monami M, Dicembrini I, Martelli D, . Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl 3):57-64
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metabol 2010;12:485-94
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
   PubMed Web of Science ®Google Scholar
• Johansen O-D, et al. Cardiovascular risk with linagliptin in patients with type 2 diabetes: a pre-specified, prospective, and adjudicated meta-analysis from a large phase III program. Poster presentation (30-LB), American Diabetes Association, 2011
   Google Scholar
• Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;:CD006423
   Google Scholar
• Esposito K, Mosca C, Brancario C, et al. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin 2011;27:1519-28
   PubMed Web of Science ®Google Scholar
• Monami M, Iacomelli I, Marchionni N, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, et al. 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, et al. DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Mannucci E, Rotella CM. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutr Metab Cardiovasc Dis 2008;18:639-45
   PubMed Web of Science ®Google Scholar
• Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009;160:909-17
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
   PubMed Web of Science ®Google Scholar
• Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011;13:594-603
   PubMed Web of Science ®Google Scholar
• Bunck MC, Cornér A, Eliasson B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010;212:223-9
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids. Systematic review and meta-analysis. Adv Ther 2012;29:14-25
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gethmann A, Götze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006;49:452-8
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rizvi AA, Spinas GA, et al. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs 2009;18:1495-503
   PubMed Web of Science ®Google Scholar
• Vilsbøll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Exp Opin Invest Drugs 2007;16:231-7
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-61
   PubMed Web of Science ®Google Scholar
• Davidson MH. Cardiovascular effects of glucagon-like peptide-1 agonists. Am J Cardiol 2011;108(3 Suppl):33-41B
   Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
   PubMed Web of Science ®Google Scholar
• Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2010. doi: 10.1111/j.1755-5922.2010.00256.x
   Google Scholar
• Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242-52
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-61
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9
   PubMed Web of Science ®Google Scholar
• Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:824-9
   PubMed Web of Science ®Google Scholar
• Kavianipour M, Ehlers MR, Malmberg K, et al. Glucagon-like peptide-1(7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003;24:569-78
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Doverspike A, Hentosz T, et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious dogs. J Pharmacol Exp 2005;312:303-8
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51
   PubMed Web of Science ®Google Scholar
• Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and post-ischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317:1106-13
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, et al. Myocardial ischemia-reperfusion injury is attenuated by intact glucagon-like peptide-1(GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drug Ther 2007;21:253-6
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5
   PubMed Web of Science ®Google Scholar
• Ravassa S, Zudaire A, Carr RD, et al. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol 2011;300:H1361-72
   PubMed Web of Science ®Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and independent pathways. Circulation 2008;117:2340-50
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improved left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H2401-8
   PubMed Web of Science ®Google Scholar
• Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146(1–3):243-9
   PubMed Web of Science ®Google Scholar
• Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-10
   PubMed Web of Science ®Google Scholar
• Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-83
   PubMed Web of Science ®Google Scholar
• Kristensen J, Mortensen UM, Schmidt M, et al. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009;9:31
   PubMed Web of Science ®Google Scholar
• Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2011 Sep 14 (epub ahead of print)
   Google Scholar
• Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-73
   PubMed Web of Science ®Google Scholar
• Ye Y, Keyes KT, Zhang C, et al. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010;298:H1454-65
   PubMed Web of Science ®Google Scholar
• Yin M, Silljé HH, Meissner M, et al. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011;10:85
   PubMed Web of Science ®Google Scholar
• Lenski M, Kazakov A, Marx N, et al. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011;51:906-18
   PubMed Web of Science ®Google Scholar
• Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:195-201
   PubMed Web of Science ®Google Scholar
• Ozyazgan S, Kutluata N, Afşar S, et al. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 2005;74:119-26
   PubMed Web of Science ®Google Scholar
• Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007;293:E1289-95
   PubMed Web of Science ®Google Scholar
• Cabou C, Vachoux C, Campistron G, et al. Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ. Diabetes 2011;60:2245-56
   PubMed Web of Science ®Google Scholar
• Gardiner SM, March JE, Kemp PA, et al. Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats. Br J Pharmacol 2008;154:60-71
   PubMed Web of Science ®Google Scholar
• Nathanson D, Erdogdu O, Pernow J, et al. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept 2009;157(1–3):8-13
   PubMed Web of Science ®Google Scholar
• Liu H, Dear AE, Knudsen LB, et al. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009;201:59-66
   PubMed Web of Science ®Google Scholar
• Gaspari T, Liu H, Welungoda I, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res 2011;8:117-24
   PubMed Web of Science ®Google Scholar
• Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010;53:2256-63
   PubMed Web of Science ®Google Scholar
• Schisano B, Harte AL, Lois K, et al. GLP–1 analogue, liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul Pept 2011 Nov 26. (epub ahead of print)
   Google Scholar
• Oeseburg H, de Boer RA, Buikema H, et al. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30:1407-14
   PubMed Web of Science ®Google Scholar
• Erdogdu O, Nathanson D, Sjöholm A, et al. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010;325(1–2):26-35
   PubMed Web of Science ®Google Scholar
• Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010;59:1030-7
   PubMed Web of Science ®Google Scholar
• Goto H, Nomiyama T, Mita T, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011;405:79-84
   PubMed Web of Science ®Google Scholar
• Koska J, Schwartz EA, Mullin MP, et al. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010;33:1028-30
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Takeuchi M, et al. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res 2011;43:731-4
   PubMed Web of Science ®Google Scholar
• Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010;33:1607-9
   PubMed Web of Science ®Google Scholar